HeartBeam seeks FDA approval of its platform technology to detect heart attacks

Aug. 16, 2022 9:06 AM ETHeartBeam, Inc. (BEAT)By: Anuron Mitra, SA News Editor
  • HeartBeam (NASDAQ:BEAT) on Tuesday said it was seeking a U.S. FDA approval for its platform technology used in detecting and diagnosing heart attacks.
  • The company submitted a so-called 510(k) application to FDA for the HeartBeam AIMI platform technology.
  • The HeartBeam

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.